Elmind Capital LP Purchases Shares of 984,931 Viridian Therapeutics, Inc. $VRDN

Elmind Capital LP purchased a new stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 984,931 shares of the company's stock, valued at approximately $18,093,182. Viridian Therapeutics comprises approximately 0.0% of Elmind Capital LP's holdings, making the stock its 8th biggest position. Elmind Capital LP owned 0.87% of Viridian Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Viridian Therapeutics by 29.6% in the fourth quarter. Vanguard Group Inc. now owns 5,612,144 shares of the company's stock worth $174,650,000 after acquiring an additional 1,280,161 shares in the last quarter. Commodore Capital LP grew its stake in shares of Viridian Therapeutics by 35.4% during the 2nd quarter. Commodore Capital LP now owns 4,875,000 shares of the company's stock worth $68,152,000 after purchasing an additional 1,275,000 shares during the period. State Street Corp grew its position in shares of Viridian Therapeutics by 35.7% in the fourth quarter. State Street Corp now owns 3,466,560 shares of the company's stock valued at $107,879,000 after purchasing an additional 912,394 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Viridian Therapeutics by 42.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 3,439,414 shares of the company's stock worth $107,036,000 after purchasing an additional 1,021,310 shares during the last quarter. Finally, Perceptive Advisors LLC raised its stake in shares of Viridian Therapeutics by 108.1% during the fourth quarter. Perceptive Advisors LLC now owns 3,042,703 shares of the company's stock valued at $94,689,000 after purchasing an additional 1,580,303 shares in the last quarter.

Viridian Therapeutics Price Performance

Shares of VRDN traded down $0.65 during mid-day trading on Friday, hitting $23.23. The company's stock had a trading volume of 502,479 shares, compared to its average volume of 2,152,657. The stock has a market capitalization of $2.63 billion, a price-to-earnings ratio of -6.89 and a beta of 0.91. The firm has a 50-day moving average price of $20.43 and a 200 day moving average price of $20.74. Viridian Therapeutics, Inc. has a fifty-two week low of $13.18 and a fifty-two week high of $34.29. The company has a debt-to-equity ratio of 0.43, a current ratio of 16.95 and a quick ratio of 16.95.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($1.05) earnings per share for the quarter, missing analysts' consensus estimates of ($1.03) by ($0.02). Viridian Therapeutics had a negative return on equity of 72.97% and a negative net margin of 505.86%.The firm had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.06 million. On average, research analysts predict that Viridian Therapeutics, Inc. will post -4.07 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Jennifer Tousignant sold 14,212 shares of the company's stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $24.50, for a total transaction of $348,194.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 2.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

VRDN has been the topic of a number of recent research reports. The Goldman Sachs Group reaffirmed a "buy" rating and set a $39.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, June 30th. Weiss Ratings downgraded Viridian Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, June 30th. Truist Financial lifted their price target on Viridian Therapeutics from $38.00 to $39.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Needham & Company LLC restated a "buy" rating and set a $32.00 price objective on shares of Viridian Therapeutics in a research report on Monday, June 29th. Finally, Stifel Nicolaus set a $39.00 target price on shares of Viridian Therapeutics in a research report on Wednesday, May 13th. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $38.54.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc NASDAQ: VRDN is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company's lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.